Physician profile
Paul E Damski
NPI 1700853884
$5,591.92
in general payments reported to CMS, 2019-2025
48 companies · $53.19 in 2025
The $53.19 reported for 2025 was less than what a typical Neurology (Psychiatry & Neurology) provider received nationally (typical 2025 total: $454).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,413 · 2020: $1,830 · 2021: $1,834 · 2022: $253 · 2023: $157 · 2024: $51.37 · 2025: $53.19.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $262.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $261.73 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Ucb, INC. | $902.39 | 2019-2023 | Cimzia |
| Amgen INC. | $815.98 | 2019-2021 | |
| Novartis Pharmaceuticals Corporation | $425.36 | 2019-2021 | |
| Abbvie INC. | $408.71 | 2021-2025 | Botox, Ubrelvy |
| Adamas Pharmaceuticals, INC. | $373.65 | 2019-2021 | |
| Mallinckrodt Hospital Products INC. | $249.13 | 2020-2021 | |
| Acorda Therapeutics, INC | $242.18 | 2019-2021 | |
| Allergan, INC. | $192.92 | 2019-2022 | |
| Teva Pharmaceuticals USA, INC. | $157.83 | 2019-2021 | |
| Biogen, INC. | $109.88 | 2020-2021 | |
| Lilly USA, LLC | $109.69 | 2019-2021 | |
| Harmony Biosciences LLC | $107.76 | 2020-2021 | |
| Tanabe Pharma America, INC. | $107.33 | 2019-2021 | |
| Eisai INC. | $104.04 | 2021 | |
| Zyla Life Sciences, INC. | $88.07 | 2019-2020 |
Show all 48 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Paul Damski listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.